Saturday 17 October 2026
Export PEPG’s income statement to Excel — free account
PepGen, Inc.
PEPG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 62.9% and free cash flow grew 33.0%, each against the same quarter a year earlier.
2.60
0.07
+2.77%
Follow PEPG
PepGen, Inc. (PEPG) P/E ratio
PepGen, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | n/m |
| WHWK Whitehawk Therapeutics, Inc. compare | n/m |
| UPB Upstream Bio, Inc. compare | n/m |
| DTIL Precision BioSciences, Inc. compare | n/m |
| ACOG Alpha Cognition Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| PEPG PepGen, Inc. | n/m |
| ORMP Oramed Pharmaceuticals Inc. compare | 1.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)